bioAffinity Technologies
BIAF

$1.32

3.97%

Market Cap: $17.8M

About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Employees: 75

Industrials Commercial Physical & Biological Research

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

78% more capital invested

Capital invested by funds: $484K [Q1] → $863K (+$379K) [Q2]

21% more funds holding

Funds holding: 14 [Q1] → 17 (+3) [Q2]

1.33% more ownership

Funds ownership: 2.09% [Q1] → 3.43% (+1.33%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$6

355%

upside

Avg. target

$6

355%

upside

High target

$6

355%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Maxim Group

Anthony Vendetti

42% 1-year accuracy

5 / 12 met price target

355%upside

$6

Buy

Initiated

23 Jul 2024

See Analyst Rankings

Financial journalist opinion

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--J. Michael Edwards replaces Michael Dougherty as bioAffinity CFO; Dougherty is leaving for a position in the energy sector in the Pacific Northwest.

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports financial results and operational highlights for the quarter ended June 30, 2024.

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAffinity Technologies (NASDAQ: BIAF) warrant exercise agreements dated August 2, 2024, with three existing accredited investors, such accredited investors have exercised outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants") at an exercise price that was reduced from $1.64 to $1.25 per share, for gross cash proceeds of approximately $1,302,083 and in consideration of such exercise, the exercising holders received in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 1,302,083 shares of common stock (equal to 125% of the shares of common stock issued in connection with the exercise of the Existing Warrants).

WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million.

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants").

WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of registered direct offering and concurrent private placement and warrant inducement.

bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET).

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies raises the 2024 full-year forecast for sales of CyPath Lung, a noninvasive test for lung cancer, by 85%.

bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET).

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients.

bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests

See News Rankings